drugset
drugset / Trial / NCT04801095

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

NCT04801095 ↗

Phase 1 Unknown 100 enrolled Wellmarker Bio Covance · collab
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.

Timeline

Start
2021-07-14
Primary completion
2025-08-08
Completion
2025-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject WM-S1-030 Unknown — Oral

Indications

cholangiocarcinoma colorectal cancer head and neck cancer lung cancer malignant pancreatic neoplasm metastatic neoplasm